Zeteo Tech Awarded Competitive Grant From the National Science Foundation

SYKESVILLE, Md.–(BUSINESS WIRE)–Zeteo Tech, the biodefense and medical device company that has developed a revolutionary new class of fieldable biological mass spectrometers, has been awarded a National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant for $256,000. The grant will be leveraged for research and development on its COVID-19 Fully Automated Disinfection System (CFADS) to help rapidly return aircraft and subway cars safely to service and disinfect public gathering spaces.

https://www.businesswire.com/news/home/20210817005218/en/Zeteo-Tech-Awarded-Competitive-Grant-From-the-National-Science-Foundation

2020 Tibbetts Award Winner – Zeteo Tech, Inc.

Zeteo Tech’s mass spectrometry technology identifies airborne microbes, proteins and lipids, and can be used to screen for infectious diseases or for the identification of aerosolized bio-threats in near real-time ‒ allowing critical infrastructure protection & near real-time screening for disease at the point-of-care.

https://www.tibbettsawards.com/zeteo-tech/

Zeteo Tech Appoints Former U.S. Assistant Secretary of Defense Andrew Weber to Board of Directors

SYKESVILLE, Md., July 29, 2020 /PRNewswire/ — Zeteo Tech, the biodefense and medical device company that has developed a revolutionary new class of fieldable biological mass spectrometers, today announced that the Honorable Andrew Weber has joined its Board of Directors. Mr. Weber served as the Assistant Secretary of Defense for Nuclear, Chemical & Biological Defense Programs under President Obama.

“Andy has dedicated much of his professional career working to strengthen our Nation’s security and response to nuclear, chemical, and biological threats,” said Wayne Bryden, PhD, President and CEO of Zeteo Tech. “We are delighted that he is joining the Board, and his unmatched wealth of knowledge and experience will be greatly utilized as Zeteo continues to grow its commercial and government offerings.”

Zeteo Tech’s proprietary digitalMALDI® technology pushes mass spectrometry innovation to a new level of sensitivity and specificity, enabling its instruments to obtain biomarker measurements from individual particles in the bioaerosol and then complete a biomarker-specific molecular identification in seconds. A combination of proprietary bioaerosol processing and MALDI mass spectrometry enables the technology’s ground-breaking advances to eliminate environmental background. By discretizing the sample in time, the analysis is exceptionally fast, sensitive and specific.

In addition to Mr. Weber’s public service as the Assistant Secretary of Defense for Nuclear, Chemical & Biological Defense Programs, he was a driving force behind Nunn-Lugar Cooperative Threat Reduction efforts to remove weapons-grade uranium from Kazakhstan and Georgia and nuclear-capable MiG-29 aircraft from Moldova, to reduce biological weapons threats, and to destroy Libyan and Syrian chemical weapons stockpiles. Mr. Weber also coordinated leadership of the international Ebola response for the U.S. Department of State.

Prior to joining the Pentagon as Advisor for Threat Reduction Policy in December 1996, Mr. Weber was posted abroad as a U.S. Foreign Service Officer in Saudi Arabia, Germany, Kazakhstan, and Hong Kong. Mr. Weber is an independent consultant and a Strategic Advisor for Ginkgo BioWorks. He serves on the Boards of Healthcare Ready and the Arms Control Association, and the James Martin Center for Non-proliferation Studies International Advisory Council.

Mr. Weber taught at the Georgetown University Graduate School of Foreign Service for seven years and was a Senior Fellow at the Harvard Kennedy School’s Belfer Center for Science and International Affairs. Mr. Weber graduated from Cornell University and holds a Master of Science in Foreign Service (MSFS) degree from Georgetown University. He is a member of the Council on Foreign Relations and a Senior Fellow at the Council on Strategic Risks, a non-partisan, non-profit think tank working against existential threats.

For more information about Zeteo Tech, please visit https://zeteotech1.wpengine.com.

About Zeteo Tech
Zeteo Tech is a venture-backed biodefense and medical device company that has developed a revolutionary new class of fieldable biological mass spectrometers. Its instruments identify airborne microbes, proteins and lipids, and can be used to screen for infectious disease and other bio-threats. Its innovative and patent-pending time of flight mass spectrometry technology, digitalMALDI®, enables fully-automated and near real-time identification of bio-threats in operational environments and dramatically lowers cost-of-ownership relative to the biomolecular reagent-based systems being launched for biodefense applications.

CONTACT
Rob Haralson for Zeteo Tech
rhh@anzupartners.com, (202) 674-6679

Zeteo Tech Awarded $6.5M DHS S&T Contract to Develop and Test digitalMALDI™ Real-Time Biological Threat Detection Technology

Sykesville, Md., April 15, 2019 /PRNewswire/ — Zeteo Tech, the biodefense and medical device company that has developed a revolutionary new class of fieldable biological mass spectrometers, today announced that it has been awarded a contract of up to $6.5 million (including options) from the U.S. Department of Homeland Security (DHS) to develop and test a new sensor technology that enables real-time detection of aerosolized biological threat agents including bacteria, viruses, and toxins. The contract was awarded in support of the Department’s Science and Technology Directorate (S&T).

“We are excited to have been selected for this award to assist the U.S. Department of Homeland Security with its ongoing efforts to improve detection and response times to potential bioterrorism attacks or naturally occurring biological incidents,” said Dr. Wayne Bryden, President and CEO of Zeteo Tech. “Our team’s deep expertise with developing fieldable and real-time biological mass spectrometers is perfectly aligned to help DHS achieve its objective of protecting citizens and critical infrastructures from biological threats.”

DHS S&T is working to develop, test, and deploy new technologies that will decrease the time required to detect a biological incident. Current systems can require up to 12-36 hours to detect an aerosolized biological threat agent and are costly to operate. The sensor to be developed under this program is intended to contain component technologies that would have both trigger and detector functions, and improve current capabilities by:

  • Reducing the amount of time required to detect the presence of a biological threat following release from the current 12-36 hour timeframe down to minutes
  • Increasing the total number of biological threats that can be detected over current technologies
  • Significantly lowering deployment, operations, and maintenance costs on a per sensor basis

“By combining both trigger and detector technologies, the sensor we are developing offers the potential for continuous air monitoring with the ability to rapidly and accurately identify biological particles indicative of a bioterrorist event,” said Mike McLoughlin, VP of Research at Zeteo Tech.

For more information about Zeteo Tech, please visit https://zeteotech1.wpengine.com.

###

About Zeteo Tech

Zeteo Tech is a venture-backed biodefense and medical device company that has developed a revolutionary new class of fieldable biological mass spectrometers. Its instruments identify airborne microbes, proteins and lipids, and can be used to screen for infectious disease and other bio-threats. Its innovative and patent-pending time of flight mass spectrometry technology, digitalMALDI®, enables fully-automated and near real-time identification of bio-threats in operational environments and dramatically lowers cost-of-ownership relative to the biomolecular reagent-based systems currently deployed for biodefense applications.

Zeteo Tech is backed by venture capital firm Anzu Partners, which invests in breakthrough industrial technologies.

Zeteo Tech Raises $3.5M in Series A Funding Round

SYKESVILLE, Md., April 15, 2019 /PRNewswire/ — Zeteo Tech, the biodefense and medical device company that has developed a revolutionary new class of fieldable biological mass spectrometers, today announced that it has raised $3.5 million in seed stage funding from industrial technology venture capital firm Anzu Partners. The funding will be used for the continued development of its digitalMALDI® technology and the commercialization of its biological mass spectrometers used to identify airborne infectious disease and bio-terror threats.

“Zeteo Tech’s mass spectrometry systems enable fully-automated and near real-time identification of bio-threats in operational environments, said Dr. Wayne Bryden, President and CEO of Zeteo Tech. “This infusion of capital from Anzu Partners will help us accelerate our commercialization timeline to ensure our compact, low-power instruments can be deployed to the applications and geographical regions that need it the most.”

Zeteo Tech’s digitalMALDI® technology pushes the innovation to a whole new level of sensitivity and specificity, enabling its instruments to obtain biomarker measurements from individual particles in the bioaerosol and then complete a biomarker-specific molecular identification in seconds A combination of proprietary bioaerosol processing and MALDI mass spectrometry enables the technology’s ground-breaking advances to eliminate environmental background. By discretizing the sample in time, the analysis is exceptionally fast, sensitive and specific.

For more information about Zeteo Tech, please visit https://zeteotech1.wpengine.com.

About Zeteo Tech
Zeteo Tech is a venture-backed biodefense and medical device company that has developed a revolutionary new class of fieldable biological mass spectrometers. Its instruments identify airborne microbes, proteins and lipids, and can be used to screen for infectious disease and other bio-threats. Its innovative and patent-pending time of flight mass spectrometry technology, digitalMALDI®, enables fully-automated and near real-time identification of bio-threats in operational environments and dramatically lowers cost-of-ownership relative to the biomolecular reagent-based systems being launched for biodefense applications.

About Anzu Partners
Anzu Partners is a venture capital and private equity firm that invests in breakthrough industrial technologies. Anzu teams with entrepreneurs to develop and commercialize technological innovations by providing capital and deep expertise in business development, market positioning, global connectivity, and operations. For more information, please visit https://anzupartners.com. On Twitter: @anzupartners.